Driven by disciplined medical cost management and improved margins in its Optum units, the company raised its full-year 2026 adjusted profit forecast to at least $20.50 per share, up from a previous range of $19.50 to $20. The results, released October 13, 2026, were accompanied by a statement from CEO Stephen Hemsley, who noted that the figures reflect the discipline and execution our teams are bringing to every part of our business, as we continue evolving UnitedHealth Group to deliver a simpler, more supportive experience for patients and the clinicians who care for them.
Third-Quarter Revenue Falls Below 2025 But Beats Estimates
While this represents a slight decline from the $113.161 billion recorded in the same period of 2025, the figure outperformed consensus analyst estimates of approximately $111 billion. Through the first nine months of 2026, the company generated $336.4 billion in revenue, exceeding the $334.4 billion reported for the same period in 2025. Profitability also saw a strong boost; the company earned $4.1 billion in the third quarter of 2026, compared to $2.3 billion in the third quarter of 2025. Total profit for the first nine months of the year reached $15.9 billion, an increase from the $12 billion reported through the first three quarters of the prior year.
Medical Cost Management Drives Margin Gains
This marked an improvement from the 89.9% recorded in the third quarter of 2025.
This contraction was influenced by a decline in membership across government-backed programs. Total medical customers for the insurance division stood at 48.3 million in the third quarter, down from 50.1 million in the year-ago quarter.
Optum Health Boosts Operating Margins Despite Revenue Dip
The Optum division, encompassing clinical care, health technology, and pharmacy services, reported $66.9 billion in revenue, compared to $69.2 billion in the third quarter of 2025. Despite the revenue dip, the unit improved its margins. Optum Health, which had previously faced regulatory and cost challenges—representing an $11 billion blow to the unit over three years—saw its operating margin rise to 3.2% in the third quarter of 2026, up from 0.2% in the third quarter of 2025. This recovery was bolstered by the decision to exit less favorable health plan contracts that had previously dragged on earnings, as well as growth in artificial-intelligence-enabled tools within the Optum Insight unit, which contributed to a 38% profit increase for that specific segment.
Analysts Weigh Medicare Advantage Ratings and Revenue Headwinds
As the company prepares for the Medicare Advantage enrollment period beginning October 15, management highlighted that over 69% of members are currently enrolled in plans rated four stars or higher for 2027. While this is a decrease from the 78% share seen in 2026, the company stated that these ratings were in line with expectations. Analysts remain divided on the financial trajectory of these ratings. Piper Sandler analyst Jessica Tassan reiterated a Buy
rating, describing the results as resilient and underappreciated.
Conversely, TD Cowen analyst Ryan Langston maintained a Hold
rating, noting that the decline in star ratings could result in a revenue headwind of approximately $1.5 billion in 2028, or about $13 per-member-per-month.
Looking ahead, Wall Street expects full-year EPS to grow 7.6% from $20.41 to $21.95. The company’s focus remains on margin improvement over market share, particularly within its risk-taking operations, as it balances the competitive environment of the healthcare industry with its long-term target of 13% to 16%.